secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lifeloc Technologies, Inc (LCTC)
CIK:        0001493137
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001079973-24-000486
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifeloc reports 2023 revenue $9.33M, net profit $206K vs loss prior year
------------------------------------------------------------------------

- Net revenue $9.330M (+10% YoY); net profit $206K ($0.08 diluted EPS) vs net loss $456K ($0.19 loss) in 2022.
- Gross margin improved to 43.3% from 36.3% due to price increases, lower depreciation, easing supply constraints.
- R&D investment increased 32% YoY focused on SpinDx 'Lab on a Disk' drug detection platform.
- Beta testing of SpinDx delta-9-THC saliva test expected later 2024; commercialization projected 2025.
- CEO says supply constraints no longer significant; L-series devices gaining approvals and market penetration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1493137/000107997324000486/0001079973-24-000486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1493137/000107997324000486/lclc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-24-000486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer